title: The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
abstract: OBJECTIVE
  The aim of this study was to assess the efficacy of sirolimus-based immunosuppression vs. conventional prophylaxis therapy in preventing cytomegalovirus (CMV) infection or disease in liver transplantation recipients.
  
  
  METHODS
  One hundred and twenty-seven consecutive liver transplant recipients, with a minimum of one-yr follow-up from 2008 to 2013 in the first affiliated hospital of Nanchang University, were retrospectively divided into the sirolimus-treated (n = 51) and ganciclovir-treated (n = 76) groups. The CMV incidence, rejection events, and survival rate were compared.
  
  
  RESULTS
  The overall incidences of CMV events were decreased but did not reach statistical significance in the sirolimus arm compared with the ganciclovir arm (p > 0.05) at one yr after liver transplantation. There was no significant difference in the rejection incidence and survival rates between the two groups.
  
  
  CONCLUSIONS
  Sirolimus-based immunosuppression had a lower incidence of CMV infection compared with conventional prophylaxis therapy and did not increase rejection risks and mortality after liver transplantation, indicating that with the use of an mammalian target-of-rapamycin (mTOR)-inhibitor, CMV prophylaxis may be dispensable.
authors: Department of Thoracic Surgery, the First Affiliated Hospital of Nanchang University, Nanchang, China.
authors: Liu
authors: L
authors: Sheng
authors: The Department of Hepatobiliary and Pancreatic Surgery and Center of Organ Transplantation, the First Affiliated Hospital of Nanchang University, Nanchang, China.
authors: Shi
authors: S
authors: Jun
authors: The Department of Hepatobiliary and Pancreatic Surgery and Center of Organ Transplantation, the First Affiliated Hospital of Nanchang University, Nanchang, China.
authors: Li
authors: L
authors: Jianfeng
authors: The Department of Hepatobiliary and Pancreatic Surgery and Center of Organ Transplantation, the First Affiliated Hospital of Nanchang University, Nanchang, China.
authors: Gao
authors: G
authors: Lianghui
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015774:Ganciclovir; D020123:Sirolimus
keywords: cytomegalovirus; effect; liver transplantation; prophylaxis therapy; sirolimus